Search
forLearn
1 / 1 resultsResearch
5 / 18 results
research Thyroid Hormone Receptor Agonist Promotes Hair Growth in Mice
TDM10842, a thyroid hormone receptor activator, was found to effectively promote hair growth in mice.
research Serum Drug Level-Related Sodium Valproate-Induced Hair Loss
High levels of the seizure medication sodium valproate can cause hair loss.
research Anterior Extra-Dural Clinoidectomy in the Approach to Supratentorial Skull Base Meningiomas: A Series of 142 Cases
Cyproterone acetate is a safe treatment that causes mild feminizing effects and is more effective with added estrogens.
research Metabolic Syndrome and the Skin: A More Than Superficial Association
Some skin conditions may indicate metabolic syndrome, which could help with early detection and management of related health issues.
research Epidermal Stem Cells Manipulated by pDNA-VEGF165/CYD-PEI Nanoparticles Loaded Gelatin/β-TCP Matrix as a Therapeutic Agent and Gene Delivery Vehicle for Wound Healing
The gelatin/β-TCP scaffold with nanoparticles improves wound healing and skin regeneration.
Community Join
5 / 31 resultscommunity Why TDM-105795 is not much talked about like GT20029 and HMI 115 despite having far better Trial results?
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
community TDM-105795, a new hair loss treatment that actually works!
A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.
community TDM-105795 phase 2 results are in!
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.